Updated track record demonstrates significantly increased success rate for drug candidates validated by Attana
Just over a year ago, a retroactive study was published on Attana´s track record in drug development in IBI (International Biopharmaceutical Industry), read the full article here. Today, updated results were published and the number of analyzed candidates for Attana in the preclinical phase amounts to 103 compared to 77 just over a year ago. The validated candidates have come further in the development process today, and the success rate is still significantly higher than industry average.
Of the 103 analyzed candidates, 36 were validated by Attana. 12 of the 36 validated drug candidates have been financed and begun clinical studies. Of these 12, 7 have reached phase II in clinical studies, 2 have recently finished phase II, and 3 are currently in the last phase, phase III. 1 of the 12 validated candidates in clinical studies has ended due to insufficient improved efficacy compared to the control.
Of the unqualified candidates, one candidate continued with clinical studies. In accordance with Attana´s prediction, this molecule showed too low effect in phase II and the project has now ended.
The updated results show a 100% success rate for Attana´s candidates in the transition between phase I and II. This is considerably higher than the industry average of 63%, which demonstrates Attana´s usefulness as a new tox-test. Also, in the transition between phase II and phase III, Attana shows a higher success rate of 86% compared to the industry average of 31%. So far, all candidates in phase III show successful results. Altogether, Attana´s validated drug candidates are 4.4 times more successful in phase I & II than the industry average.
Developing drugs is extremely costly. The average R&D cost of a drug amounts to approximately 2 billion dollars, of which around half is related to clinical studies. Although most of the candidates that begin clinical studies reach phase II, only 22% reach phase III and less than 10% are approved, mainly due to inadequate testing and analysis in pre-clinical phases.
CEO, Teodor Aastrup comments:
”We founded Attana since we were convinced that we could increase the success rate in clinical studies by studying the target- and off-target interactions in a relevant biological way. Attana´s validated drug candidates clearly demonstrate the importance of ensuring effective interactions and to eliminate off-target interactions.”
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
